371 related articles for article (PubMed ID: 35930129)
1. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
[TBL] [Abstract][Full Text] [Related]
2. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
3. Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
Hendren NS; Roth LR; Grodin JL
Curr Heart Fail Rep; 2020 Jun; 17(3):77-83. PubMed ID: 32356182
[TBL] [Abstract][Full Text] [Related]
4. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era.
Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA
J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490
[TBL] [Abstract][Full Text] [Related]
5. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Ruberg FL; Maurer MS
JAMA; 2024 Mar; 331(9):778-791. PubMed ID: 38441582
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
Law S; Bezard M; Petrie A; Chacko L; Cohen OC; Ravichandran S; Ogunbiyi O; Kharoubi M; Ganeshananthan S; Ganeshananthan S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Damy T; Fontana M; Gillmore JD
Eur Heart J; 2022 Jul; 43(27):2622-2632. PubMed ID: 35608040
[TBL] [Abstract][Full Text] [Related]
8. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
10. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
Gopal DM; Ruberg FL; Siddiqi OK
Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive risk stratification of patients with transthyretin amyloidosis.
Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
13. Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers.
Nagano N; Muranaka A; Nishikawa R; Ohwada W; Kouzu H; Kamiyama N; Fujito T; Mochizuki A; Nagahara D; Nakanishi M; Ohkubo Y; Hisahara S; Nakao S; Katoh N; Ishikawa A; Sakurai A; Yano T
Int Heart J; 2022; 63(1):168-175. PubMed ID: 35095067
[TBL] [Abstract][Full Text] [Related]
14. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
[TBL] [Abstract][Full Text] [Related]
15. ATTR Epidemiology, Genetics, and Prognostic Factors.
Obi CA; Mostertz WC; Griffin JM; Judge DP
Methodist Debakey Cardiovasc J; 2022; 18(2):17-26. PubMed ID: 35414855
[TBL] [Abstract][Full Text] [Related]
16. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction.
Jiang X; Labaudinière R; Buxbaum JN; Monteiro C; Novais M; Coelho T; Kelly JW
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33597308
[TBL] [Abstract][Full Text] [Related]
17. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin treatment and cardiovascular outcome in RBP4/TTR
Li Z; Lv F; Wen X; Guo C; Li L; Cai X; Lin C; Zhang M; Yang W; Ji L
ESC Heart Fail; 2024 Feb; 11(1):179-188. PubMed ID: 37877450
[TBL] [Abstract][Full Text] [Related]
19. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
